Compare Citius Pharmaceuticals Inc (CTXR) vs iShares MSCI Singapore ETF (EWS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs iShares MSCI Singapore ETF — how do they compare? Citius Pharmaceuticals Inc trades at $0.54 (market cap $14.64M), while iShares MSCI Singapore ETF trades at $32.08. The key difference: iShares MSCI Singapore ETF is trading nearer its 52-week high, Citius Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| CTXR | EWS | |
|---|---|---|
Market Cap | $14.64M | — |
Sector | Health | Broad Market / Factor |
52-Week High | $1.82 | $31.64 |
52-Week Low | $0.53 | $26.47 |
Enterprise Value | $10.86M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.54, down 7.33% in the last session, with a bearish technical signal from moving averages. The company reported a net loss of $37.43M for 2025 and has missed earnings expectations for the last three quarters. Recent news highlights progress with LYMPHIR, including Phase 1 data presentations at ASCO and international expansion, alongside $5.6M in net revenue for the first half of 2026.
Despite a high analyst buy consensus (83%), CTXR faces significant fundamental challenges with negative profitability and cash burn. Investment opportunity hinges on successful commercialization of LYMPHIR, but risks include ongoing losses, dilution from recent financing, and clinical execution uncertainties. The stock remains speculative with high risk-reward dynamics.
EWS trades at $31.43, down 0.66% today, with a bullish technical signal from moving averages but bearish oscillators. The ETF offers a 3.97% dividend yield and is near its 2007 all-time high of $31.94. Recent news highlights Singapore's economic strength and financial sector reforms as key drivers.
Outlook remains positive due to Singapore's stability and AI infrastructure growth, though concentrated holdings and overbought RSI levels pose near-term risks. The ETF appeals for Asian diversification with consistent income, but investors should monitor financial sector exposure and regional economic shifts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About iShares MSCI Singapore ETF
EWS tracks the MSCI Singapore 25/50 Index, providing targeted exposure to large and mid-cap companies in Singapore. It is heavily weighted toward the financial, industrial, and real estate sectors, serving as a liquid tool for accessing Singapore's stable, dividend-oriented developed economy.
Read more on EWS →
